Prospective clinical experience with research biopsies in breast cancer patients

Ines Vaz-Luis, Catherine A. Zeghibe, Elizabeth S. Frank, Jessica Sohl, Kimberly E. Washington, Stuart G. Silverman, Joseph M. Fonte, Erica L. Mayer, Beth A. Overmoyer, Andrea Richardson, Ian E. Krop, Eric P. Winer, Nancy U. Lin

Research output: Contribution to journalArticle

Abstract

There are ethical concerns regarding the performance of biopsies in patients for research purposes. We examined our single-institution experience regarding acceptance, safety, and success rate with research biopsies in patients with breast cancer. Among patients with data from paired samples, receptor status agreement between primary and metastatic samples was examined, either on first recurrence or after progression on one or more lines of therapy. An IRB-approved prospective study at the Dana-Farber Cancer Institute collects research biopsies as additional passes at the time of a clinical biopsy (AB, additional biopsy) or as a separate procedure for banking purposes (RPOB, research purposes only biopsy). Biopsies are not linked to a specific therapeutic or correlative trial. Grade 2-5 adverse events are prospectively collected. 151 patients were included in the analytic cohort (total procedures = 161); 80.8 % underwent AB, 17.2 % underwent RPOB, and 2.0 % underwent both AB and RPOB. Most patients were white (88.7 %) with a performance status of 0-1 (94.0 %). 96.0 % of patients underwent a biopsy in the setting of known or suspected metastatic disease. Receptor status between primary cancer and recurrent research biopsies differed in 43.2 % of patients with available data (18.8 % among patients who underwent the research biopsy before any systemic treatment, 48.1 % after treatment). Tissue was successfully collected in 92.3 % of patients undergoing AB and 100 % patients undergoing RPOB. Only three (2.0 %) patients had adverse events ≥grade-2: one grade-2 pain; one grade-2 pneumothorax; and one grade-3 pain. Our experience suggests research biopsies can be performed safely with a high rate of successful tissue collection. Consistent with previous reports we found a high rate of discordance between primary and metastatic samples, which was even higher among treated patients. This supports continued efforts to study tissue samples at multiple points in a patient's disease course.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalBreast Cancer Research and Treatment
Volume142
Issue number1
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Breast Neoplasms
Biopsy
Research
Pain
Research Ethics Committees
Pneumothorax
Therapeutics
Neoplasms
Prospective Studies
Safety
Recurrence

Keywords

  • Breast cancer
  • Patients' preferences
  • Receptor discordance
  • Research biopsies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vaz-Luis, I., Zeghibe, C. A., Frank, E. S., Sohl, J., Washington, K. E., Silverman, S. G., ... Lin, N. U. (2013). Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Research and Treatment, 142(1), 203-209. https://doi.org/10.1007/s10549-013-2717-5

Prospective clinical experience with research biopsies in breast cancer patients. / Vaz-Luis, Ines; Zeghibe, Catherine A.; Frank, Elizabeth S.; Sohl, Jessica; Washington, Kimberly E.; Silverman, Stuart G.; Fonte, Joseph M.; Mayer, Erica L.; Overmoyer, Beth A.; Richardson, Andrea; Krop, Ian E.; Winer, Eric P.; Lin, Nancy U.

In: Breast Cancer Research and Treatment, Vol. 142, No. 1, 11.2013, p. 203-209.

Research output: Contribution to journalArticle

Vaz-Luis, I, Zeghibe, CA, Frank, ES, Sohl, J, Washington, KE, Silverman, SG, Fonte, JM, Mayer, EL, Overmoyer, BA, Richardson, A, Krop, IE, Winer, EP & Lin, NU 2013, 'Prospective clinical experience with research biopsies in breast cancer patients', Breast Cancer Research and Treatment, vol. 142, no. 1, pp. 203-209. https://doi.org/10.1007/s10549-013-2717-5
Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG et al. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Research and Treatment. 2013 Nov;142(1):203-209. https://doi.org/10.1007/s10549-013-2717-5
Vaz-Luis, Ines ; Zeghibe, Catherine A. ; Frank, Elizabeth S. ; Sohl, Jessica ; Washington, Kimberly E. ; Silverman, Stuart G. ; Fonte, Joseph M. ; Mayer, Erica L. ; Overmoyer, Beth A. ; Richardson, Andrea ; Krop, Ian E. ; Winer, Eric P. ; Lin, Nancy U. / Prospective clinical experience with research biopsies in breast cancer patients. In: Breast Cancer Research and Treatment. 2013 ; Vol. 142, No. 1. pp. 203-209.
@article{a5fb372035d94427960c7d241890844e,
title = "Prospective clinical experience with research biopsies in breast cancer patients",
abstract = "There are ethical concerns regarding the performance of biopsies in patients for research purposes. We examined our single-institution experience regarding acceptance, safety, and success rate with research biopsies in patients with breast cancer. Among patients with data from paired samples, receptor status agreement between primary and metastatic samples was examined, either on first recurrence or after progression on one or more lines of therapy. An IRB-approved prospective study at the Dana-Farber Cancer Institute collects research biopsies as additional passes at the time of a clinical biopsy (AB, additional biopsy) or as a separate procedure for banking purposes (RPOB, research purposes only biopsy). Biopsies are not linked to a specific therapeutic or correlative trial. Grade 2-5 adverse events are prospectively collected. 151 patients were included in the analytic cohort (total procedures = 161); 80.8 {\%} underwent AB, 17.2 {\%} underwent RPOB, and 2.0 {\%} underwent both AB and RPOB. Most patients were white (88.7 {\%}) with a performance status of 0-1 (94.0 {\%}). 96.0 {\%} of patients underwent a biopsy in the setting of known or suspected metastatic disease. Receptor status between primary cancer and recurrent research biopsies differed in 43.2 {\%} of patients with available data (18.8 {\%} among patients who underwent the research biopsy before any systemic treatment, 48.1 {\%} after treatment). Tissue was successfully collected in 92.3 {\%} of patients undergoing AB and 100 {\%} patients undergoing RPOB. Only three (2.0 {\%}) patients had adverse events ≥grade-2: one grade-2 pain; one grade-2 pneumothorax; and one grade-3 pain. Our experience suggests research biopsies can be performed safely with a high rate of successful tissue collection. Consistent with previous reports we found a high rate of discordance between primary and metastatic samples, which was even higher among treated patients. This supports continued efforts to study tissue samples at multiple points in a patient's disease course.",
keywords = "Breast cancer, Patients' preferences, Receptor discordance, Research biopsies",
author = "Ines Vaz-Luis and Zeghibe, {Catherine A.} and Frank, {Elizabeth S.} and Jessica Sohl and Washington, {Kimberly E.} and Silverman, {Stuart G.} and Fonte, {Joseph M.} and Mayer, {Erica L.} and Overmoyer, {Beth A.} and Andrea Richardson and Krop, {Ian E.} and Winer, {Eric P.} and Lin, {Nancy U.}",
year = "2013",
month = "11",
doi = "10.1007/s10549-013-2717-5",
language = "English (US)",
volume = "142",
pages = "203--209",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Prospective clinical experience with research biopsies in breast cancer patients

AU - Vaz-Luis, Ines

AU - Zeghibe, Catherine A.

AU - Frank, Elizabeth S.

AU - Sohl, Jessica

AU - Washington, Kimberly E.

AU - Silverman, Stuart G.

AU - Fonte, Joseph M.

AU - Mayer, Erica L.

AU - Overmoyer, Beth A.

AU - Richardson, Andrea

AU - Krop, Ian E.

AU - Winer, Eric P.

AU - Lin, Nancy U.

PY - 2013/11

Y1 - 2013/11

N2 - There are ethical concerns regarding the performance of biopsies in patients for research purposes. We examined our single-institution experience regarding acceptance, safety, and success rate with research biopsies in patients with breast cancer. Among patients with data from paired samples, receptor status agreement between primary and metastatic samples was examined, either on first recurrence or after progression on one or more lines of therapy. An IRB-approved prospective study at the Dana-Farber Cancer Institute collects research biopsies as additional passes at the time of a clinical biopsy (AB, additional biopsy) or as a separate procedure for banking purposes (RPOB, research purposes only biopsy). Biopsies are not linked to a specific therapeutic or correlative trial. Grade 2-5 adverse events are prospectively collected. 151 patients were included in the analytic cohort (total procedures = 161); 80.8 % underwent AB, 17.2 % underwent RPOB, and 2.0 % underwent both AB and RPOB. Most patients were white (88.7 %) with a performance status of 0-1 (94.0 %). 96.0 % of patients underwent a biopsy in the setting of known or suspected metastatic disease. Receptor status between primary cancer and recurrent research biopsies differed in 43.2 % of patients with available data (18.8 % among patients who underwent the research biopsy before any systemic treatment, 48.1 % after treatment). Tissue was successfully collected in 92.3 % of patients undergoing AB and 100 % patients undergoing RPOB. Only three (2.0 %) patients had adverse events ≥grade-2: one grade-2 pain; one grade-2 pneumothorax; and one grade-3 pain. Our experience suggests research biopsies can be performed safely with a high rate of successful tissue collection. Consistent with previous reports we found a high rate of discordance between primary and metastatic samples, which was even higher among treated patients. This supports continued efforts to study tissue samples at multiple points in a patient's disease course.

AB - There are ethical concerns regarding the performance of biopsies in patients for research purposes. We examined our single-institution experience regarding acceptance, safety, and success rate with research biopsies in patients with breast cancer. Among patients with data from paired samples, receptor status agreement between primary and metastatic samples was examined, either on first recurrence or after progression on one or more lines of therapy. An IRB-approved prospective study at the Dana-Farber Cancer Institute collects research biopsies as additional passes at the time of a clinical biopsy (AB, additional biopsy) or as a separate procedure for banking purposes (RPOB, research purposes only biopsy). Biopsies are not linked to a specific therapeutic or correlative trial. Grade 2-5 adverse events are prospectively collected. 151 patients were included in the analytic cohort (total procedures = 161); 80.8 % underwent AB, 17.2 % underwent RPOB, and 2.0 % underwent both AB and RPOB. Most patients were white (88.7 %) with a performance status of 0-1 (94.0 %). 96.0 % of patients underwent a biopsy in the setting of known or suspected metastatic disease. Receptor status between primary cancer and recurrent research biopsies differed in 43.2 % of patients with available data (18.8 % among patients who underwent the research biopsy before any systemic treatment, 48.1 % after treatment). Tissue was successfully collected in 92.3 % of patients undergoing AB and 100 % patients undergoing RPOB. Only three (2.0 %) patients had adverse events ≥grade-2: one grade-2 pain; one grade-2 pneumothorax; and one grade-3 pain. Our experience suggests research biopsies can be performed safely with a high rate of successful tissue collection. Consistent with previous reports we found a high rate of discordance between primary and metastatic samples, which was even higher among treated patients. This supports continued efforts to study tissue samples at multiple points in a patient's disease course.

KW - Breast cancer

KW - Patients' preferences

KW - Receptor discordance

KW - Research biopsies

UR - http://www.scopus.com/inward/record.url?scp=84888255968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888255968&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2717-5

DO - 10.1007/s10549-013-2717-5

M3 - Article

C2 - 24113744

AN - SCOPUS:84888255968

VL - 142

SP - 203

EP - 209

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -